Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Protagonist Therapeutics (PTGX) over the last 9 years, with Q3 2025 value amounting to $7.5 million.

  • Protagonist Therapeutics' Change in Accured Expenses rose 4262.76% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 15599.72%. This contributed to the annual value of $4.3 million for FY2024, which is 17663.03% up from last year.
  • As of Q3 2025, Protagonist Therapeutics' Change in Accured Expenses stood at $7.5 million, which was up 4262.76% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Protagonist Therapeutics' Change in Accured Expenses registered a high of $13.0 million during Q3 2021, and its lowest value of -$11.8 million during Q1 2025.
  • Over the past 5 years, Protagonist Therapeutics' median Change in Accured Expenses value was $2.1 million (recorded in 2021), while the average stood at $223210.5.
  • As far as peak fluctuations go, Protagonist Therapeutics' Change in Accured Expenses surged by 37332.61% in 2021, and later tumbled by 65928.68% in 2022.
  • Protagonist Therapeutics' Change in Accured Expenses (Quarter) stood at $4.7 million in 2021, then tumbled by 197.53% to -$4.6 million in 2022, then decreased by 16.35% to -$5.3 million in 2023, then skyrocketed by 160.47% to $3.2 million in 2024, then soared by 133.74% to $7.5 million in 2025.
  • Its Change in Accured Expenses stands at $7.5 million for Q3 2025, versus $3.4 million for Q2 2025 and -$11.8 million for Q1 2025.